Clinical Trial Update: TAC/MTX vs. TAC/MMF/PTCY for Prevention of Graft-versus-Host Disease and Microbiome and Immune Reconstitution Study (BMT CTN 1703/1801) [Phase 3]

View source ↗

Summary

Phase 3 trial comparing TAC/MTX versus TAC/MMF/PTCY for graft-versus-host disease prevention and microbiome/immune reconstitution in patients with acute leukemi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia
• Lymphoma
• Myelodysplastic Syndrome
• Myelogenous Leukemia

Drugs mentioned

• TAC/MMF/PTCY (Tacrolimus with Mycophenolate Mofetil and Post-Transplant Cyclophosphamide)
• TAC/MTX (Tacrolimus with Methotrexate)

Snippet

Sponsor: Medical College of Wisconsin | Conditions: Acute Leukemia, Chronic Myelogenous Leukemia (CML) | Phase 3 | Status: COMPLETED | Results posted: 2024-01-12